5 Key Takeaways

• 1

  The phase 2 Alluvium trial evaluated vamikibart's efficacy and safety in treatment-naïve patients with diabetic macular edema (DME).

• 2

  Vamikibart demonstrated average gains of approximately 6 letters in best-corrected visual acuity (BCVA) across all dosing arms at weeks 44 and 48.

• 3

  30% to 40% of treatment-naïve patients achieved resolution of DME, with central subfield thickness improvements of 50 µm to 70 µm from baseline.

• 4

  Higher doses of vamikibart were associated with increased intraocular inflammation, while low rates of cataract and elevated intraocular pressure were observed.

• 5

  The findings support further exploration of combining anti-IL-6 and anti-VEGF therapies to address both inflammatory and angiogenic pathways in DME.